Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.82 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.82 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.58 |
| ▸ | BPTF | Q12830 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036654 | 0.91 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF | |
| Hydrochloric Acid SCHEMBL2491811 | 0.89 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF | |
| Hydrochloric Acid SCHEMBL29692664 | 0.89 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF | |
| SCHEMBL25104854 | 0.80 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF | |
| SCHEMBL15379222 | 0.76 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF | |
| SCHEMBL1977615 | 0.76 | LMNA (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF | |
| SCHEMBL15379224 | 0.76 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF | |
| SCHEMBL1977612 | 0.76 | LMNA (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF | |
| SCHEMBL5375111 | 0.76 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL31200657 | 0.76 | LMNA (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1210277-C | Heteroaryl diazabicycloalkanes, their prepn. and use | NEUROSEARCH AS (DK) | 2005-07-13 | — | — | CN | claimed |
| EP-1177196-B1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2004-03-10 | — | — | EP | claimed |
| US-6552012-B2 | 3-(6-Chloro-(3-pyridazinyl))-9-methyl-3,9-diazabicyclo(4.2.1)-nonane, for example; Alzheimer's disease, Parkinson's disease, memory dysfunction, smoking cessation, drug abuse, drug dependence; cholinergic ligands | NEUROSEARCH A/S (DK) | 2003-04-22 | — | — | US | claimed |
| JP-2002543201-A | — | — | 2002-12-17 | — | — | JP | claimed |
| CN-1349533-A | Heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2002-05-15 | — | — | CN | claimed |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | claimed |
| EP-1177196-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-02-06 | — | — | EP | claimed |
| WO-2000066586-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-09 | — | — | WO | claimed |
| CN-1210277-C | Heteroaryl diazabicycloalkanes, their prepn. and use | NEUROSEARCH AS (DK) | 2005-07-13 | — | — | CN | disclosed |
| EP-1177196-B1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2004-03-10 | — | — | EP | disclosed |
| US-6552012-B2 | 3-(6-Chloro-(3-pyridazinyl))-9-methyl-3,9-diazabicyclo(4.2.1)-nonane, for example; Alzheimer's disease, Parkinson's disease, memory dysfunction, smoking cessation, drug abuse, drug dependence; cholinergic ligands | NEUROSEARCH A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| CN-1349533-A | Heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2002-05-15 | — | — | CN | disclosed |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| EP-1177196-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000066586-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA2 | CHRNB2 4/4885CHRNA4 13/4885CHRNB4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.